95 results on '"Knox, J. J."'
Search Results
2. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials
3. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials*
4. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy
5. A phase I–II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798)
6. Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience
7. Health utility scores from EQ-5D and health-related quality of life in patients with esophageal cancer: a real-world cross-sectional study
8. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor tyrosine-kinase inhibitor therapy
9. Smoking: attitudes of Costa Rican physicians and opportunities for intervention
10. Adjuvant sunitinib following chemoradiotherapy and surgery for locally advanced esophageal cancer: a phase II trial
11. Relationship between Karnofsky Performance Status (KPS) and tumor response: analysis of the RECORD-1 phase 3 trial of everolimus in patients with advanced renal cell carcinoma (RCC)
12. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.
13. Chemotherapy in Hormone Refractory Prostate Cancer
14. First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC
15. Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Statement
16. Adjuvant sunitinib (Su) for locally advanced esophageal cancer (LAEC): Results of a phase II trial.
17. Outcomes following sequential trials of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC).
18. Adjuvant therapy in the treatment of biliary tract cancer (BTC): A systematic review and meta-analysis.
19. Analysis of the relationship between Karnofsky performance status (KPS) and tumor response in the RECORD-1 phase III trial of everolimus in patients with advanced renal cell carcinoma (RCC).
20. Use of serum and tissue biomarker analysis embedded in a phase II clinical trial of cytarabine in castration-refractory prostate cancer to investigate prostate cancer biology.
21. Preoperative sorafenib (Sor) and cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC).
22. Use of serum and tissue biomarker analysis embedded in a phase II clinical trial of cytarabine in castration-refractory prostate cancer to investigate prostate cancer biology.
23. Brain metastases in patients treated with targeted therapy for metastatic renal cell carcinoma (mRCC).
24. Biliary tract cancer (BTC) in the older adult: Complex decisions for complex patients.
25. Adjuvant Chemoradiation for Gastric Cancer with Infusional 5-Fluorouracil and Cisplatin: A Phase I Study
26. First-line everolimus followed by second-line sunitinib versus the opposite treatment sequence in patients with metastatic renal cell carcinoma (mRCC).
27. The impact of body mass index (BMI) and body surface area (BSA) on treatment outcome to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma: Results from a large international collaboration.
28. The interaction between smoking status and disease stage on non-small cell lung cancer (NSCLC) survival.
29. A unified prognostic model for first- and second-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from a large international study.
30. Linifanib phase II trial in patients with advanced hepatocellular carcinoma (HCC).
31. Long-term sorafenib (SOR) safety profile in more than 700 patients (pts) with renal-cell carcinoma (RCC) treated for 12 to 42 months (mos).
32. Sorafenib (SOR) safety profile in more than 4,600 patients (pts) with renal cell carcinoma (RCC): Assessment at 3-month (mo) intervals using an integrated database of eight company-sponsored studies.
33. Prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted agents: Results from a large multicenter study
34. A phase II study of single agent abraxane as second-line therapy in patients with advanced urothelial carcinoma
35. A phase II study of ABT-869 in hepatocellular carcinoma (HCC): Interim analysis
36. The effects of sorafenib and sunitinib on bone turnover markers in patients with bone metastases from renal cell carcinoma
37. Failure of initial VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC): What next?
38. Adjuvant sunitinib following chemoradiotherapy (CRT) and surgery for esophageal cancer: A phase II trial
39. Managing Toxicities and Optimal Dosing of Targeted Drugs in Advanced Kidney Cancer
40. Safety and efficacy of sorafenib in elderly patients (pts) ≥65 years: A subset analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America
41. Rationale and evidence for the use of sunitnib to treat patients with malignant paraganglioma/pheochromocytoma (MPP)
42. A phase I–II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798)
43. Phase I study of stereotactic radiotherapy for unresectable hepatobiliary cancer and liver metastases
44. Sorafenib for the treatment of metastatic renal cancer (MRC) in the real world: The Princess Margaret Hospital (PMH) experience
45. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy
46. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Long-term outcomes in first-line patients (pts)
47. A phase II trial of oblimersen sodium (G3139) in combination with doxorubicin (DOX) in advanced hepatocellular carcinoma (HCC). NCI protocol # 5798
48. A phase I/II study of vaccination with autologous dendritic cells (DCs) transfected with autologous amplified tumor-derived mRNA in patients with stage IV renal cell carcinoma (RCC)
49. Toxicity and outcomes of adjuvant chemoradiotherapy in patients with resected gastric adenocarcinoma
50. Preliminary results of a phase I study of stereotactic radiotherapy for unresectable primary and metastatic liver cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.